Nasdaq

Annexon Provides Update on ARCHER II Global Registrational Program in Geographic Atrophy

Patient Dosing Initiated in Phase 3 ARCHER II Trial of C1q Inhibitor ANX007; Topline Data Expected in Second Half 2026 Additional Data from Phase 2 ARCHER Trial Demonstrated Both Significant Vision ...
Seeking Alpha

Annexon Outlines Global Registrational Program for ANX007 in Geographic Atrophy with FDA Alignment on Vision Preservation as Primary Endpoint

Alignment with FDA on Best Corrected Visual Acuity ≥ 15-Letter Loss as Primary Outcome Measure - Representing the Highest Value Outcome to Patients and Physicians ARCHER II, a Global Sham-Controlled ...

ONL Therapeutics Announces First European Patient Randomized in its Global Phase 2 GALAXY Trial of Xelafaslatide (ONL1204) in Patients with Geographic Atrophy (GA) Associated ...

Enrollment begins in Switzerland as the company continues to activate clinical sites beyond the U.S. market ANN ARBOR, Mich., March 16, 2026 /PRNewswire/ -- ONL Therapeutics, Inc., a clinical-stage ...
Healio

World Geographic Atrophy Day aims to empower individuals, heighten awareness

Please provide your email address to receive an email when new articles are posted on . Dec. 5 is World Geographic Atrophy Day, a new initiative that seeks to empower individuals with this advanced ...